Overview

New Adjuvant Treatment of Locally Advanced Resectable Gastric Cancer With Carelizumab and XELOX

Status:
Recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of carelizumab combined with XELOX regimen in neoadjuvant treatment of locally advanced resectable gastric cancer

Phase:

N/A

Details

Lead Sponsor:

Tang-Du Hospital